Skip to main content
Top

Open Access 03-02-2025 | Public Health | Original Research

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit

Authors: Johnna Perdrizet, An Ta, Liping Huang, Warisa Wannaadisai, Aleksandar Ilic, Kyla Hayford, Ayman Sabra

Published in: Infectious Diseases and Therapy

Login to get access

Abstract

Introduction

Despite the approval of a 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use in many regions globally, integration of PCV20 into national immunization programs (NIPs) is delayed in some countries. We explored the public health and economic benefits forfeited by postponing transitions from lower-valent pneumococcal conjugate vaccines (PCVs) to PCV20.

Methods

A targeted literature review (TLR) identified modeling studies comparing the public health and economic impact of PCV20 versus 13-valent PCV (PCV13) or 15-valent PCV (PCV15) in pediatric NIPs. Only studies with accessible models underwent data extraction and analysis. Foregone public health (pneumococcal disease cases/disease-related deaths) and economic (medical/non-medical costs) outcomes, defined as the projected incremental differences between the outcomes associated with PCV20 and lower-valent PCVs, were calculated over 2 years following PCV20 implementation (per year and month). Discount rates for all outcomes were adjusted to 0% given the short time horizon and for consistency across analyses.

Results

The TLR identified models from 13 countries globally. The monthly health benefits forgone due to delayed transitions from PCV13 to PCV20 ranged between 40 (Slovakia) and 1740 (Canada) pneumococcal disease cases averted in the first year of delay across populations, increasing by between 1.5 (Sweden) and 15–16 times (Germany and Mexico) in the second year. Forgone cumulative disease-related deaths averted ranged from 18 (Spain) to 2657 (Germany) and forgone cumulative direct medical cost-savings ranged from 930 thousand Euros (Portugal) to 146 million Euros (Germany) due to delayed transitions from PCV13 to PCV20 over 2 years. Similar, but slightly reduced, benefits were forfeited with delayed transitions from PCV15 to PCV20.

Conclusion

Delays in implementing PCV20 into pediatric NIPs were projected to have substantial negative public health and economic consequences. These results underscore the necessity for national immunization technical advisory groups, policymakers, health organizations, and manufacturers to accelerate replacement of lower-valent standard-of-care PCVs with PCV20.
Appendix
Available only for authorised users
Literature
9.
go back to reference U.S. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years. Available from: https://www.cdc.gov/acip/grade/PCV20-child.html. Accessed Oct 2024. U.S. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years. Available from: https://​www.​cdc.​gov/​acip/​grade/​PCV20-child.​html. Accessed Oct 2024.
10.
go back to reference Ta A, Kühne F, Laurenz M, von Eiff C, Warren S, Perdrizet J. Cost-effectiveness of PCV20 to prevent pneumococcal disease in the pediatric population: a German societal perspective analysis. Infect Dis Ther. 2024;13(6):1333–58.CrossRefPubMedPubMedCentral Ta A, Kühne F, Laurenz M, von Eiff C, Warren S, Perdrizet J. Cost-effectiveness of PCV20 to prevent pneumococcal disease in the pediatric population: a German societal perspective analysis. Infect Dis Ther. 2024;13(6):1333–58.CrossRefPubMedPubMedCentral
11.
go back to reference Shinjoh M, Togo K, Hayamizu T, et al. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan. Expert Rev Vaccin. 2024;23(1):485–97.CrossRef Shinjoh M, Togo K, Hayamizu T, et al. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan. Expert Rev Vaccin. 2024;23(1):485–97.CrossRef
12.
go back to reference Lytle D, Grajales Beltrán AG, Perdrizet J, et al. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Hum Vaccin Immunother. 2023;19(2):2257426.CrossRefPubMedPubMedCentral Lytle D, Grajales Beltrán AG, Perdrizet J, et al. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Hum Vaccin Immunother. 2023;19(2):2257426.CrossRefPubMedPubMedCentral
13.
go back to reference Warren S, Barmpouni M, Kossyvaki V, Gourzoulidis G, Perdrizet J. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to higher-valent options in Greek infants. Vaccines (Basel). 2023;11(8):1369.CrossRefPubMed Warren S, Barmpouni M, Kossyvaki V, Gourzoulidis G, Perdrizet J. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to higher-valent options in Greek infants. Vaccines (Basel). 2023;11(8):1369.CrossRefPubMed
14.
go back to reference Wilson M, Lucas A, Mendes D, et al. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023;11(7):1168.CrossRefPubMed Wilson M, Lucas A, Mendes D, et al. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023;11(7):1168.CrossRefPubMed
15.
go back to reference Huang L, McDade CL, Perdrizet JE, et al. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023;12(3):933–50.CrossRefPubMedPubMedCentral Huang L, McDade CL, Perdrizet JE, et al. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023;12(3):933–50.CrossRefPubMedPubMedCentral
16.
go back to reference Rey-Ares L, Ta A, Freigofaite D, et al. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. Vaccine. 2024;42(23):126043.CrossRefPubMed Rey-Ares L, Ta A, Freigofaite D, et al. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. Vaccine. 2024;42(23):126043.CrossRefPubMed
17.
go back to reference Rozenbaum MH, Chilson E, Farkouh R, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine among US children with underlying medical conditions. Infect Dis Ther. 2024;13(4):745–60.CrossRefPubMedPubMedCentral Rozenbaum MH, Chilson E, Farkouh R, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine among US children with underlying medical conditions. Infect Dis Ther. 2024;13(4):745–60.CrossRefPubMedPubMedCentral
18.
go back to reference Rozenbaum MH, Huang L, Cane A, et al. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13. J Med Econ. 2024;27(1):644–52.CrossRefPubMed Rozenbaum MH, Huang L, Cane A, et al. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13. J Med Econ. 2024;27(1):644–52.CrossRefPubMed
19.
go back to reference Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022;40(49):7057–64.CrossRefPubMed Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022;40(49):7057–64.CrossRefPubMed
20.
go back to reference Rey-Ares L, Averin A, Mac Mullen M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Argentinean adults. Infect Dis Ther. 2024;13(6):1235–51.CrossRefPubMedPubMedCentral Rey-Ares L, Averin A, Mac Mullen M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Argentinean adults. Infect Dis Ther. 2024;13(6):1235–51.CrossRefPubMedPubMedCentral
21.
go back to reference Kang DW, Kim CR, Song JY, Park SK. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine. 2024;42(4):871–8.CrossRefPubMed Kang DW, Kim CR, Song JY, Park SK. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine. 2024;42(4):871–8.CrossRefPubMed
22.
go back to reference Gourzoulidis G, Barmpouni M, Kossyvaki V, Vietri J, Tzanetakos C. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece. Front Public Health. 2023;11:1229524.CrossRefPubMedPubMedCentral Gourzoulidis G, Barmpouni M, Kossyvaki V, Vietri J, Tzanetakos C. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece. Front Public Health. 2023;11:1229524.CrossRefPubMedPubMedCentral
23.
go back to reference Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285–95.CrossRefPubMed Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285–95.CrossRefPubMed
24.
go back to reference Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of four pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023;12(7):1809–21.CrossRefPubMedPubMedCentral Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of four pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023;12(7):1809–21.CrossRefPubMedPubMedCentral
25.
go back to reference Senders S, Klein NP, Tamimi N, et al. A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2024;43(6):596–603.CrossRefPubMedPubMedCentral Senders S, Klein NP, Tamimi N, et al. A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2024;43(6):596–603.CrossRefPubMedPubMedCentral
26.
go back to reference Virgilio R, Pagliaro A, Iantomasi R, et al. Cost-effectiveness of a 20-valent pediatric pneumonoccal conjugate vaccine compared with a 15-valent pneumococcal conjugate vaccine in Italy. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Lisbon, Portugal: 8–12 May, 2023. Virgilio R, Pagliaro A, Iantomasi R, et al. Cost-effectiveness of a 20-valent pediatric pneumonoccal conjugate vaccine compared with a 15-valent pneumococcal conjugate vaccine in Italy. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Lisbon, Portugal: 8–12 May, 2023.
27.
go back to reference Wannaadisai W, Kuchta L, Šebo P, Hroncova D, Perdrizet J. Cost-effectiveness of a 20-valent pediatric pneumococcal conjugate vaccine compared with 13-valent and 15-valent pneumococcal conjugate vaccines in Slovakia. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark: May 20–24, 2024. Wannaadisai W, Kuchta L, Šebo P, Hroncova D, Perdrizet J. Cost-effectiveness of a 20-valent pediatric pneumococcal conjugate vaccine compared with 13-valent and 15-valent pneumococcal conjugate vaccines in Slovakia. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark: May 20–24, 2024.
28.
go back to reference Fridh A, Palmborg A, Ta A, Freigofaite D, Warren S, Perdrizet J. A cost-effectiveness analysis of the 15-valent and 20-valent pneumococcal conjugate vaccines in the Swedish pediatric population. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark: May 20–24, 2024. Fridh A, Palmborg A, Ta A, Freigofaite D, Warren S, Perdrizet J. A cost-effectiveness analysis of the 15-valent and 20-valent pneumococcal conjugate vaccines in the Swedish pediatric population. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark: May 20–24, 2024.
29.
go back to reference Huerta J, Ta A, Freigofaite D, Torres G, Wannaadisai W, Huang L. Estimating economic and health impacts of PCV20 under different schedules compared to lower-valent alternatives in Mexican pediatric population. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark: May 20–24, 2024. Huerta J, Ta A, Freigofaite D, Torres G, Wannaadisai W, Huang L. Estimating economic and health impacts of PCV20 under different schedules compared to lower-valent alternatives in Mexican pediatric population. Presented at: European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark: May 20–24, 2024.
30.
go back to reference Kang DW, June Choe Y, Lee JY, et al. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea. Vaccine. 2024;42(22): 126000.CrossRefPubMed Kang DW, June Choe Y, Lee JY, et al. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea. Vaccine. 2024;42(22): 126000.CrossRefPubMed
31.
go back to reference Lozano V, Ta A, López-Ibáñez de Aldecoa A, Gálvez P, Méndez C, Perdrizet J. Health and economic impact of PCV20 in comparison with lower-valent alternatives to prevent pneumococcal disease in Spanish pediatric population. Presented at: European Society for Paediatric Infectious Diseases (ESPID); May 20–24, 2024; Copenhagen, Denmark. Lozano V, Ta A, López-Ibáñez de Aldecoa A, Gálvez P, Méndez C, Perdrizet J. Health and economic impact of PCV20 in comparison with lower-valent alternatives to prevent pneumococcal disease in Spanish pediatric population. Presented at: European Society for Paediatric Infectious Diseases (ESPID); May 20–24, 2024; Copenhagen, Denmark.
32.
go back to reference Teixeira R, Maia A, Horn E, et al. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine in paediatric national immunisation programme in Portugal. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Lisbon, Portugal: 23–26 April, 2022. Teixeira R, Maia A, Horn E, et al. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine in paediatric national immunisation programme in Portugal. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Lisbon, Portugal: 23–26 April, 2022.
35.
go back to reference Lauer-Fischer GmbH. LAUER-TAXER Kompetenz online. 2023. Accessed Sept 2024. Lauer-Fischer GmbH. LAUER-TAXER Kompetenz online. 2023. Accessed Sept 2024.
39.
go back to reference Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–57.CrossRefPubMedPubMedCentral Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–57.CrossRefPubMedPubMedCentral
Metadata
Title
Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit
Authors
Johnna Perdrizet
An Ta
Liping Huang
Warisa Wannaadisai
Aleksandar Ilic
Kyla Hayford
Ayman Sabra
Publication date
03-02-2025
Publisher
Springer Healthcare
Keyword
Public Health
Published in
Infectious Diseases and Therapy
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-025-01108-3

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more